RESUMEN
This retrospective study investigated the efficacy and safety of letrozole for patients with polycystic ovary syndrome (PCOS).Totally, 136 cases of infertility women with PCOS were analyzed. Of those, 68 patients received letrozole, and were assigned to Letrozole group. The other 68 cases received clomiphene, and were assigned to clomiphene group. Patients in both groups were treated up to 5 treatment cycles. The primary endpoint included infant outcomes. The secondary endpoints consisted of the number of women in conception, pregnancy, pregnancy loss, and ovulation. In addition, any kinds of adverse events were also recorded.Cases in the Letrozole group did not show better outcomes neither in primary endpoint (live birth, Pâ=â.11; birth weight, Pâ=â.95; infant gender, Pâ=â.85), nor in secondary endpoints (the number of women in conception, Pâ=â.07; pregnancy, Pâ=â.12; pregnancy loss, Pâ=â.47; pregnancy loss in first trimester, Pâ=â.70; and ovulation, Pâ=â.09), compared with cases in the clomiphene group. Moreover, no adverse events differ significantly between 2 groups.This study demonstrated that the efficacy of letrozole is not superior to the clomiphene in patients with PCOS.
Asunto(s)
Inhibidores de la Aromatasa/uso terapéutico , Clomifeno/uso terapéutico , Fármacos para la Fertilidad Femenina/uso terapéutico , Nitrilos/uso terapéutico , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Triazoles/uso terapéutico , Adulto , Inhibidores de la Aromatasa/efectos adversos , Clomifeno/efectos adversos , Femenino , Fármacos para la Fertilidad Femenina/efectos adversos , Humanos , Infertilidad Femenina/tratamiento farmacológico , Letrozol , Nitrilos/efectos adversos , Embarazo , Resultado del Embarazo , Índice de Embarazo , Estudios Retrospectivos , Resultado del Tratamiento , Triazoles/efectos adversosRESUMEN
This retrospective study investigated the effectiveness of percutaneous nerve electrical stimulation (PNES) for fatigue caused by chemotherapy for cervical cancer survivors.Totally, 83 cases of fatigue caused by chemotherapy for cervical cancer survivors were analyzed. All these cases were assigned to a treatment group (nâ=â43), and a control group (nâ=â40). Patients in the treatment group received PNES, while the subjects in the control group were on waiting list. The treatment was applied once daily for a total of 6 weeks. The primary endpoint was fatigue. It was evaluated by the Multidimensional Fatigue Inventory (MFI), and Fatigue Questionnaire (FQ). The secondary endpoints consisted of anxiety and depression. They were measured by the Hospital Anxiety and Depression Scale (HADS). All outcomes were measured before and after 6-week treatment.After treatment, PNES did not show significant difference in fatigue relief, measured by MFI (General fatigue, Pâ=â.31; Physical fatigue, Pâ=â.44; Activity, Pâ=â.36; Motivation, Pâ=â.55; Mental fatigue, Pâ=â.49), and FQ (Mental fatigue, Pâ=â.29; Physical fatigue, Pâ=â.35); and the reduction of anxiety and depression, measured by the HADS (Anxiety, Pâ=â.21; Depression, Pâ=â.17) after 6 weeks treatment between 2 groups.This study demonstrated that PNES may not benefit for cervical cancer survivors with fatigue caused by chemotherapy after 6-week treatment.
Asunto(s)
Antineoplásicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Fatiga/inducido químicamente , Fatiga/terapia , Estimulación Eléctrica Transcutánea del Nervio , Neoplasias del Cuello Uterino/tratamiento farmacológico , Adulto , Anciano , Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carboplatino/efectos adversos , Carboplatino/uso terapéutico , Fatiga/diagnóstico , Femenino , Fluorouracilo/efectos adversos , Fluorouracilo/uso terapéutico , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Cathelicidins are a family of multi-functional antimicrobial peptides found in almost all types of vertebrates, where they play vital roles in the immune system. As they possess broad-spectrum antimicrobial properties, cathelicidins are not only strongly resistant to Gram-positive and Gram-negative bacteria, fungi, and viruses, but they are also active against many antibiotic-resistant clinical bacteria, adopting a special antimicrobial mechanism that is unlikely to lead to microbial resistance. Cathelicidins likewise possess simple structures, and low hemolytic and cytotoxic activities. Collectively, these features suggest potentially novel and exciting prospects for cathelicidins' application in medicine. Here, we review the structures, classification, activities, mechanisms, as well as prospective developments in the usage and application of cathelicidin antimicrobial peptides.